27 septiembre 2015
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors of the lung and gastrointestinal tract.
http://www.sciencedaily.com/releases/2015/09/150927115556.htm
